This is a Phase 1, two-part, open-label study to evaluate the interaction of cyclosporine, probenecid, and rifampin as perpetrators with vadadustat (victim) in healthy male and female subjects.
This is a Phase 1, two-part, open-label study to evaluate the interaction of cyclosporine, probenecid, and rifampin as perpetrators with vadadustat (victim) in healthy male and female subjects. Part 1 consists of 2 arms (cyclosporine and probenecid) and Part 2 consists of 1 arm (rifampin). Twenty (20) unique subjects will be enrolled into each study arm. The PK and safety/tolerability data from Part 1 Arm 1 (cyclosporine) will determine if Part 2 (rifampin) will proceed. Subjects will be on study for up to 72 days, including a 28-day screening period, 6-10 day clinic period, and a 30-day follow-up period post last dose. Blood and/or urine samples for PK analysis will be collected at pre-defined timepoints throughout the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
40
inVentiv Health Clinique Inc.
Québec, Quebec, Canada
Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast) of vadadustat
Time frame: Up to 10 weeks
Area under plasma concentration-time curve from 0 to infinity (AUCinf) of vadadustat
Time frame: Up to 10 weeks
Maximum observed plasma concentration (Cmax) of vadadustat
Time frame: Up to 10 weeks
Time to maximum observed plasma concentration (Tmax) of vadadustat
Time frame: Up to 10 weeks
Elimination rate constant (Kel) of vadadustat
Time frame: Up to 10 weeks
Terminal half-life (t½) of vadadustat
Time frame: Up to 10 weeks
Apparent total body clearance (CL/F) of vadadustat
Time frame: Up to 10 weeks
Percent of extrapolated area under the curve from time t to infinity (%AUCextrap) of vadadustat
Time frame: Up to 10 weeks
Renal clearance (CLr) of vadadustat and vadadustat 1-O-glucuronide excretion in urine for Part 1 Arm 2 (Probenecid) only
Time frame: Up to 10 weeks
Cumulative amount excreted (Ae0-t) of vadadustat and vadadustat 1-O-glucuronide in urine for Part 1 Arm 2 (Probenecid) only
Time frame: Up to 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Oral Cyclosporine
Fraction (%) of the dose excreted (Fe%0-t) for Part 1 Arm 2 (Probenecid) only of vadadustat and vadadustat 1-O-glucuronide excretion in urine
Time frame: Up to 10 weeks
Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast) of vadadustat metabolites
Time frame: Up to 10 weeks
Area under plasma concentration-time curve from 0 to infinity (AUCinf) of vadadustat metabolites
Time frame: Up to 10 weeks
Maximum observed plasma concentration (Cmax) of vadadustat metabolites
Time frame: Up to 10 weeks
Reporting of treatment emergent adverse events as reported by the study subject
Time frame: Up to 10 weeks